Anterior Uveitis Drug Sales

Anterior Uveitis Drug Sales Market Outlook

The global anterior uveitis drug sales market is anticipated to reach USD 1.5 billion by 2035, exhibiting a robust compound annual growth rate (CAGR) of 6.5% during the forecast period from 2025 to 2035. This growth is attributed to the rising prevalence of ocular diseases, increasing awareness regarding eye health, and advancements in therapeutic options for uveitis treatment. Additionally, the growing aging population, which is more susceptible to inflammatory eye conditions, is further propelling the demand for effective uveitis therapies. Coupled with the emergence of novel drug delivery mechanisms and increasing investment in ocular research and development, these factors are expected to contribute significantly to the market's growth. Furthermore, rising healthcare expenditure and the expansion of healthcare facilities globally are likely to create more channels for drug distribution, enhancing market penetration.

Growth Factor of the Market

The anterior uveitis drug sales market is experiencing significant growth primarily due to the escalating incidence of uveitis, which is often linked to autoimmune diseases and infections. Moreover, advancements in drug formulations and administration methods are enhancing therapeutic efficacy and patient compliance, making treatments more accessible and effective. The increasing emphasis on early diagnosis and timely treatment of ocular conditions has also amplified the demand for uveitis medications. Additionally, the rise in telemedicine and digital health technologies is facilitating remote consultations, allowing patients to receive timely prescriptions for anterior uveitis treatments. Awareness campaigns led by health organizations are further educating the public on the importance of eye health, driving the demand for medical interventions and thereby boosting the market growth.

Key Highlights of the Market

• The global anterior uveitis drug sales market is projected to reach USD 1.5 billion by 2035.
• CAGR of 6.5% during the forecast period from 2025 to 2035.
• Growing prevalence of ocular diseases contributing to market expansion.
• Advancements in therapeutic options enhancing treatment efficacy.
• Increasing investment in ocular research bolstering market growth.

By Drug Type

Corticosteroids:

Corticosteroids are the cornerstone of anterior uveitis treatment due to their potent anti-inflammatory properties. These medications work by reducing inflammation and suppressing the immune response, thereby alleviating the symptoms associated with uveitis. Numerous corticosteroids, such as prednisone and dexamethasone, are administered either topically or systemically, depending on the severity of the condition. The increasing incidence of autoimmune diseases has led to a higher demand for corticosteroids in managing anterior uveitis, contributing significantly to market revenue. Additionally, the development of new formulations and delivery methods, such as sustained-release implants, is enhancing the therapeutic effects and reducing the frequency of administration, making corticosteroids a popular choice among healthcare providers.

Cycloplegic Agents:

Cycloplegic agents are often utilized in the management of anterior uveitis as they help relieve pain by paralyzing the ciliary muscle and dilating the pupil. This alleviation of muscle spasms and discomfort allows for better healing of the eye. Common cycloplegic agents include atropine and homatropine, which are frequently administered in conjunction with corticosteroids for enhanced therapeutic outcomes. As awareness regarding the importance of managing uveitis symptoms grows, the demand for cycloplegic agents has seen a steady increase, positively impacting their sales in the market. Furthermore, ongoing research into more effective formulations and administration routes is expected to bolster the uptake of these drugs in the coming years.

Nonsteroidal Anti-Inflammatory Drugs:

Nonsteroidal anti-inflammatory drugs (NSAIDs) are significant in managing anterior uveitis due to their ability to reduce inflammation and provide analgesic effects. These drugs, including indomethacin and ketorolac, are used either topically or orally, depending on the severity of the condition being treated. The rise in the prevalence of uveitis and the growing patient population seeking relief from ocular pain have driven the demand for NSAIDs in this market segment. Additionally, the increasing recognition of the importance of multimodal therapy, which incorporates NSAIDs alongside corticosteroids, is likely to enhance their market share as clinicians seek comprehensive treatment approaches to manage anterior uveitis effectively.

Immunosuppressive Agents:

Immunosuppressive agents play a crucial role in treating anterior uveitis, especially in cases where corticosteroids alone are insufficient. These medications, which include agents like azathioprine and methotrexate, help modulate the immune response and prevent recurrences of uveitis. The growing awareness of the importance of long-term management strategies for chronic conditions is driving the adoption of immunosuppressive therapies in the anterior uveitis drug sales market. Moreover, as healthcare providers gain insights into the underlying causes of uveitis, the tailored use of immunosuppressive agents is expected to gain traction, enhancing their market potential in the upcoming years.

Biologics:

Biologics are a newer class of treatments that are gaining acceptance in the management of anterior uveitis. These agents, which include medications like adalimumab and infliximab, target specific pathways in the immune system to reduce inflammation effectively. The increasing prevalence of autoimmune diseases that are associated with uveitis is driving the demand for biologics as a more targeted treatment option. Moreover, the evolving landscape of biologic therapies, including the development of biosimilars, is expected to make these treatments more accessible and cost-effective, further enhancing their uptake in the anterior uveitis drug sales market. Ongoing clinical trials and positive outcomes are likely to solidify the role of biologics in treating anterior uveitis in the future.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a critical role in the distribution of anterior uveitis drugs, offering a wide range of medications tailored for inpatient and outpatient care. These pharmacies ensure the timely availability of essential drugs for managing acute and chronic cases of uveitis. Additionally, hospital pharmacies are often involved in patient education regarding medication use, side effects, and adherence, thus improving treatment outcomes. The increasing number of hospitals and eye care facilities is expected to drive growth in this distribution channel, as more patients seek specialized care for uveitis. Furthermore, collaborations between hospitals and pharmaceutical companies are likely to enhance drug availability, reinforcing the significance of hospital pharmacies in the anterior uveitis drug sales market.

Retail Pharmacies:

Retail pharmacies serve as a primary distribution channel for anterior uveitis medications, providing patients with easier access to prescribed drugs. These pharmacies often stock a range of corticosteroids, NSAIDs, and cycloplegic agents that are commonly used in uveitis treatment. The convenience of retail pharmacies, including extended hours and locations, plays a significant role in patient adherence to medication regimens. As awareness of anterior uveitis increases, the demand for treatments dispensed through retail channels is likely to rise. Additionally, retail pharmacies often engage in promotional activities and patient counseling, further enhancing their position in the market by ensuring that patients understand their treatment options and adhere to prescribed therapies.

Online Pharmacies:

Online pharmacies are becoming increasingly popular as a distribution channel for anterior uveitis medications, driven by the rise of e-commerce and digital health solutions. The convenience of ordering medications online, coupled with the ability to receive consultations via telemedicine, has made online pharmacies a viable option for patients seeking treatment for uveitis. This distribution channel allows patients to access a broader range of medications, often at competitive prices, without the need to visit a physical pharmacy. The COVID-19 pandemic has further accelerated the adoption of online pharmacies as patients seek safe and convenient options for obtaining prescriptions. As digital platforms continue to evolve, the market for online pharmacies in the anterior uveitis drug sales segment is expected to grow significantly in the coming years.

By Route of Administration

Topical:

Topical administration is one of the most common routes for delivering anterior uveitis treatments, primarily due to its localized effect and reduced systemic side effects. Eye drops and ointments containing corticosteroids, NSAIDs, and cycloplegic agents are frequently prescribed to manage inflammation and alleviate pain. The popularity of topical medications stems from their ease of use and rapid onset of action, making them a preferred choice for both patients and physicians. As advancements in drug formulation, such as sustained-release technologies, continue to emerge, the effectiveness of topical treatments for anterior uveitis is expected to improve, solidifying this route's importance in the drug sales market.

Oral:

Oral administration of medications for anterior uveitis is often utilized when systemic treatment is necessary. Oral corticosteroids and immunosuppressive agents are commonly prescribed to manage moderate to severe cases of uveitis. This route of administration is preferred in situations where immediate relief is required, and it allows for convenient dosing schedules tailored to patient needs. The oral route also facilitates the administration of combination therapies, enhancing treatment efficacy. As new oral formulations with improved bioavailability and patient compliance continue to be developed, the demand for oral treatments in the anterior uveitis drug sales market is poised for growth.

Injectable:

Injectable medications are often reserved for cases of severe anterior uveitis that do not respond adequately to other treatment modalities. Intravitreal injections of biologics and corticosteroids provide targeted therapy directly to the affected area, offering rapid relief of inflammation and pain. The effectiveness of injectable treatments, combined with ongoing advancements in injection techniques and drug delivery systems, is expected to drive their adoption in the market. The ability to deliver high concentrations of medication directly to the site of inflammation can significantly improve patient outcomes. As clinical practice guidelines increasingly endorse the use of injectable therapies, their role in the anterior uveitis drug sales market is likely to expand.

By User

Hospitals:

Hospitals are key users of anterior uveitis medications, providing comprehensive care for patients experiencing acute and chronic cases of the condition. Due to the complexity and severity of many uveitic cases, hospitals often employ a multidisciplinary approach, involving ophthalmologists, rheumatologists, and other specialists. The demand for uveitis treatments within hospitals is driven by the increasing incidence of ocular inflammatory diseases and the need for effective management strategies. As hospitals enhance their capabilities in treating complex eye conditions, the market for anterior uveitis drugs is expected to expand, with hospitals accounting for a substantial share of the overall sales.

Clinics:

Clinics are another vital segment in the anterior uveitis drug sales market, offering accessible care for patients seeking treatment for less severe cases of uveitis. Ocular clinics often provide timely consultations and prescriptions, facilitating early management of the condition, which is crucial for preventing complications. The demand for anterior uveitis drugs in clinics is bolstered by the rising awareness of eye health and the importance of regular check-ups. As the number of specialized eye clinics continues to increase, the market for anterior uveitis medications within this user group is expected to grow significantly, providing patients with convenient access to effective treatments.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) play a pivotal role in the anterior uveitis drug sales market by providing surgical interventions for severe cases requiring immediate treatment. ASCs often perform procedures such as intravitreal injections and other surgical techniques to address complications associated with uveitis. The increasing trend toward outpatient surgical procedures is driving the demand for anterior uveitis medications within these centers. ASCs typically follow a patient-centric approach, focusing on minimizing hospital stays and promoting faster recovery, which is appealing to patients. As more patients opt for outpatient services, the role of ASCs in the anterior uveitis drug sales market is likely to grow, reinforcing their importance in providing timely and effective care.

By Region

The North American anterior uveitis drug sales market is projected to dominate the global landscape owing to the high prevalence of ocular diseases and a well-established healthcare infrastructure. With an estimated market share of approximately 40%, this region is expected to experience a CAGR of around 7% during the forecast period. The increasing number of eye care professionals and advancements in treatment options are further fueling market growth. In Europe, the demand for anterior uveitis drugs is also rising, driven by heightened awareness of eye health and a growing aging population more susceptible to inflammatory conditions. The European market is anticipated to hold a significant share, accounting for roughly 30% of the global market, as healthcare providers emphasize early diagnosis and effective management of uveitis.

In the Asia Pacific region, the anterior uveitis drug sales market is gaining momentum due to the rapid urbanization and increasing prevalence of autoimmune diseases among the population. With an estimated market share of 20%, this region is expected to showcase promising growth opportunities, driven by improved healthcare access and rising disposable incomes. Latin America and the Middle East & Africa represent smaller market segments, accounting for approximately 5% and 5% of the global market, respectively. However, increasing investments in healthcare infrastructure and the growing focus on eye health awareness are likely to drive gradual growth in these regions. Overall, the anterior uveitis drug sales market is poised for expansion globally, with each region contributing to the overall revenue growth.

Opportunities

The anterior uveitis drug sales market is poised to capitalize on several emerging opportunities, particularly with the advancements in research and development within ocular pharmacotherapy. There is a growing trend toward the development of personalized medicine, which tailors treatment plans based on individual patient profiles and responses to therapy. This shift presents a unique opportunity for pharmaceutical companies to innovate and develop targeted therapies that not only address the immediate symptoms of anterior uveitis but also tackle the underlying causes of the disease. Additionally, the integration of technology, such as telemedicine and mobile health applications, can enhance patient engagement and adherence to treatment, ultimately improving outcomes and driving market growth. The rise of biologics and biosimilars also presents an opportunity for more effective and cost-efficient treatment options, expanding access to necessary medications for patients worldwide.

Moreover, collaborations between pharmaceutical companies and healthcare providers are likely to foster the development of comprehensive care models that encompass prevention, early detection, and effective management of anterior uveitis. Educational initiatives aimed at both healthcare professionals and patients can enhance awareness about the disease, its symptoms, and the importance of timely treatment, further driving demand for anterior uveitis medications. The increasing focus on eye health, supported by government initiatives and healthcare organizations, is expected to create a conducive environment for growth in the anterior uveitis drug sales market. As the global healthcare ecosystem evolves, these opportunities will be instrumental in shaping the future of anterior uveitis treatment and driving market expansion.

Threats

Despite the growth prospects, the anterior uveitis drug sales market faces several threats that could hinder its progress. One of the primary concerns is the stringent regulatory environment surrounding the approval and marketing of pharmaceutical products. Regulatory agencies mandate rigorous testing and compliance with safety standards, which can lengthen the time to market for new treatments. This prolonged timeline can deter investment in research and development, limiting the introduction of innovative therapies for anterior uveitis. Furthermore, the emergence of generic drugs poses a significant challenge to the market, as these lower-cost alternatives can erode the market share of branded medications, impacting revenue for pharmaceutical companies.

Additionally, the increasing prevalence of adverse drug reactions and side effects associated with certain treatments may lead to reduced patient compliance, further complicating management strategies for anterior uveitis. Patients may become hesitant to adhere to prescribed regimens if they experience negative effects, ultimately impacting treatment outcomes. The market also faces competition from alternative therapies and non-pharmacological interventions that may offer viable solutions for managing uveitis symptoms. The rise of holistic approaches and natural remedies could divert patients away from conventional treatments, creating further challenges for pharmaceutical companies. Overall, navigating these threats will require strategic planning and adaptability to ensure sustained growth in the anterior uveitis drug sales market.

Restrainer factors also play a critical role in shaping the anterior uveitis drug sales market. One of the key restrictors is the high cost of advanced medications, particularly biologics and other specialized treatments. Many patients may find it challenging to afford these therapies, especially in regions with limited healthcare coverage or high out-of-pocket expenses. This financial barrier can lead to disparities in access to effective treatments, limiting market growth potential. Additionally, the complexity of managing anterior uveitis, which often requires a multidisciplinary approach and ongoing monitoring, can further strain healthcare resources, leading to potential delays in treatment. The lack of standardized treatment protocols and variability in clinical practices across different regions may also hinder the comprehensive management of anterior uveitis, creating challenges for pharmaceutical companies in promoting their products effectively.

Competitor Outlook

• AbbVie Inc.
• Alcon Laboratories, Inc.
• Novartis AG
• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Valeant Pharmaceuticals International, Inc.
• Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• Ocular Therapeutix, Inc.
• Eyepoint Pharmaceuticals, Inc.
• Genentech, Inc.
• Sun Pharmaceutical Industries Ltd.

The competitive landscape of the anterior uveitis drug sales market is characterized by a mix of established pharmaceutical giants and emerging companies, all vying for market share in this growing sector. Major players such as AbbVie and Novartis have made significant investments in research and development, bringing forward innovative therapies that have generated substantial revenue. These companies leverage extensive distribution networks and strong brand recognition to solidify their positions in the market. Moreover, the increasing focus on personalized medicine and biologics has prompted these players to enhance their product portfolios, catering to the evolving needs of patients and healthcare providers alike.

Emerging biotech firms are also making significant strides in the anterior uveitis space, often specializing in niche therapies that address specific aspects of the disease. Companies like Ocular Therapeutix and Eyepoint Pharmaceuticals are focusing on developing sustained-release formulations and novel drug delivery systems that enhance treatment efficacy and patient compliance. By leveraging advanced technologies, these companies are positioning themselves as strong contenders in the market, challenging traditional players with innovative solutions. Additionally, strategic partnerships and collaborations are becoming increasingly common, allowing companies to pool resources and expertise to expedite the development of new therapies and improve market access.

As the anterior uveitis drug sales market continues to evolve, key players will likely intensify their efforts to differentiate themselves through robust research initiatives, competitive pricing strategies, and comprehensive marketing approaches. The emphasis on patient-centric care and personalized treatment regimens is expected to drive further innovations, creating a dynamic and competitive landscape. Companies that can effectively navigate regulatory challenges and demonstrate the clinical value of their products will be well-positioned to capture market share in this lucrative sector, ensuring sustained growth and success in the anterior uveitis drug sales market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Genentech, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Holding AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Hoffmann-La Roche Ltd
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Alcon Laboratories, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Ocular Therapeutix, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Bristol-Myers Squibb Company
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Eyepoint Pharmaceuticals, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Regeneron Pharmaceuticals, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sun Pharmaceutical Industries Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Takeda Pharmaceutical Company Limited
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Valeant Pharmaceuticals International, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Anterior Uveitis Drug Sales Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Ambulatory Surgical Centers
  • 6.2 Anterior Uveitis Drug Sales Market, By Drug Type
    • 6.2.1 Corticosteroids
    • 6.2.2 Cycloplegic Agents
    • 6.2.3 Nonsteroidal Anti-Inflammatory Drugs
    • 6.2.4 Immunosuppressive Agents
    • 6.2.5 Biologics
  • 6.3 Anterior Uveitis Drug Sales Market, By Distribution Channel
    • 6.3.1 Hospital Pharmacies
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Pharmacies
  • 6.4 Anterior Uveitis Drug Sales Market, By Route of Administration
    • 6.4.1 Topical
    • 6.4.2 Oral
    • 6.4.3 Injectable

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Anterior Uveitis Drug Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Anterior Uveitis Drug Sales market is categorized based on

By Drug Type

• Corticosteroids
• Cycloplegic Agents
• Nonsteroidal Anti-Inflammatory Drugs
• Immunosuppressive Agents
• Biologics

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Route of Administration

• Topical
• Oral
• Injectable

By User

• Hospitals
• Clinics
• Ambulatory Surgical Centers

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Alcon Laboratories, Inc.
• Novartis AG
• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Valeant Pharmaceuticals International, Inc.
• Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• Ocular Therapeutix, Inc.
• Eyepoint Pharmaceuticals, Inc.
• Genentech, Inc.
• Sun Pharmaceutical Industries Ltd.